We are live on ! Find out more
EDIT icon

Editas Medicine

194 hedge funds and large institutions have $149M invested in Editas Medicine in 2025 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 47 increasing their positions, 57 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

492% more call options, than puts

Call options by funds: $4.92M | Put options by funds: $830K

64% more capital invested

Capital invested by funds: $90.9M → $149M (+$58.4M)

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

0% more funds holding

Funds holding: 194194 (0)

1.47% less ownership

Funds ownership: 49.34%47.87% (-1.5%)

18% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 57

Holders
194
Holders Change
Holders Change %
0%
% of All Funds
2.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
24
Increased
47
Reduced
57
Closed
23
Calls
$4.92M
Puts
$830K
Net Calls
+$4.09M
Net Calls Change
+$2.85M

EDIT Hedge Fund Activity: Q3 2025 in Review

194 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2025, worth a combined $149M — up 64% from $90.9M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new EDIT positions and 23 closed out — a net gain of 1 holder — while 47 added to existing stakes and 57 trimmed.

The largest buyer was BlackRock, adding an estimated $3.35M. The largest seller was Millennium Management, cutting an estimated $4.3M.

  • 194 institutional investors held Editas Medicine (EDIT) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $149M of Editas Medicine stock for Q3 2025, up 64% quarter-over-quarter.
  • 24 funds opened new Editas Medicine positions in Q3 2025 and 23 closed out, a net change of +1 holder.
  • The largest Editas Medicine buyer in Q3 2025 was BlackRock, an estimated $3.35M added.
  • The largest Editas Medicine seller in Q3 2025 was Millennium Management, an estimated $4.3M sold.

Based on aggregated 13F filings for Q3 2025.